Jeffrey Aronin, CEO of Northbrook-based Marathon Pharmaceuticals, is photographed in 2015. After the price of his company's Duchenne muscular dystrophy drug came under fire, Aronin said Feb. 13, 2017, that Marathon would pause the commercial launch of the drug.